Literature DB >> 8603457

Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice.

I Muckenschnabel1, G Bernhardt, T Spruss, A Buschauer.   

Abstract

Preclinical and clinical observations suggest that the administration of hyaluronidase (Hyase) shortly before that of chemotherapy increases the access and, thus, the effectiveness of anticancer drugs in tumors. To examine this hypotheses as well as the selectivity of such a therapeutic approach potentially beneficial in isolated limb perfusion, the Hyase-induced distribution of melphalan was measured in tumor-bearing nude mice with respect to the mode of drug administration using RP-18 ion-pair high-performance liquid chromatography (HPLC) with fluorimetric detection. Melphalan alone (50 micromol/kg) or a combination of melphalan (50 micro mol/kg) and Hyase (100,000 IU/kg) was injected either i.p. or s.c. in the vicinity of the tumors. The s.c. melphalan injection caused a 4-fold rise in melphalan concentration (59 microM) in the tumors as compared with i.p. application (15 microM). Only minor effects were observed with respect to the route of melphalan application on its distribution in other tissues (ca. 13 microM in plasma, 15 microM in muscle, 30 microM in the liver, 26 microM in the kidney, and 21 microM in the testicle). Irrespective of the route of Hyase coadministration, the enzyme increased the concentration of i.p. injected melphalan in all tissues to ca. 20 microM in the tumor, 15 microM in plasma, 27 microM in muscle, 40 microM in the liver, 29 microM in the kidney, and 28 microM in the testicle. In contrast, s.c. injected melphalan was selectively accumulated by the tumors after both s.c. and i.p. Hyase administration (462 and 388 microM, respectively). Melphalan enrichment in the tumors was higher (16- to 32-fold higher than in the other tissues) after i.p. administration of Hyase since, in contrast to s.c. injection of the enzyme, its i.p. administration caused a decrease in the concentration of the cytostatic in all other tissues as compared with the s.c. administration of melphalan alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603457     DOI: 10.1007/s002800050452

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Authors:  Clifford J Whatcott; Haiyong Han; Richard G Posner; Galen Hostetter; Daniel D Von Hoff
Journal:  Cancer Discov       Date:  2011-09       Impact factor: 39.397

Review 2.  Cell membrane-derived nanomaterials for biomedical applications.

Authors:  Ronnie H Fang; Yao Jiang; Jean C Fang; Liangfang Zhang
Journal:  Biomaterials       Date:  2017-03-01       Impact factor: 12.479

3.  Targeting tumor extracellular matrix activates the tumor-draining lymph nodes.

Authors:  Alexander J Najibi; Ting-Yu Shih; David K Y Zhang; Junzhe Lou; Miguel C Sobral; Hua Wang; Maxence O Dellacherie; Kwasi Adu-Berchie; David J Mooney
Journal:  Cancer Immunol Immunother       Date:  2022-05-07       Impact factor: 6.630

Review 4.  Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.

Authors:  Clifford J Whatcott; Haiyong Han; Daniel D Von Hoff
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.